Concerto Biosciences

Concerto Biosciences rebuilds microbial communities in, on, and around us to heal our bodies and our planet. Products that rebuild microbial communities do not yet exist because no one can map the vast inter-species interaction networks responsible for community behavior. Concerto’s cofounders therefore invented the first-ever ultra-high-throughput platform to experimentally measure millions of microbial interactions. Concerto maps interaction networks that reveal a new class of products called “ensembles”—combinations of microbes that work in concert to shepherd damaged microbial communities to health. The opportunities are enormous: Concerto will become the premier inventor of ensembles across medicine and agriculture, reinventing humanity’s relationship with microbes.

Concerto Biosciences headquartered in United States, North America, operates in the Big Data, Biotechnology, Life Science, Medical, Biopharma sector. The company focuses on Big Data and has secured $1.0B in funding across 40 round(s). With a team of 11-50 employees, Concerto Biosciences is actively contributing to advancements in Big Data. Their latest funding round, Series A - Concerto Biosciences, raised $24.5M. Discover more about their projects, partnerships, and impact on our platform.